In response to Furst et al, "possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin" [2] (multiple letters)

Biological Psychiatry

Volumn 52, Issue 9, 2002, Pages 914-915

  Pierre, Joseph M ^a   Wirshing, Donna A ^a   Wirshing, William C ^a   Geller, Wayne ^b   Smith, Mark ^b   Winter, Helen ^b   Brecher, Martin ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; HALOPERIDOL; KETOCONAZOLE; MEVINOLIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; ZIPRASIDONE;

CALCULATION; DRUG BLOOD LEVEL; DRUG SENSITIVITY; HEART RATE; HYPOTHESIS; LETTER; PRIORITY JOURNAL; QT INTERVAL;

EID: 0036838506     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01494-4     Document Type: Letter

References (6)

1. A.P. Beelen K. Yeo L.D. Lewis Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone Hum Exp Toxicol 20 2001 215 219
2. P. Gajwani L. Pozuelo G.E. Tesar QT interval prolongation associated with quetiapine (Seroquel) overdose Psychosomatics 41 2000 63 65
3. J.A. Gillespie J.D. Hoehns M.W. Kelly Comment Sudden cardiac death with clozapine and sertraline combination Ann Pharmacother 35 2001 1671 1672
4. S. Gupta P. Masand A.J. Kothari Cardiovascular side effects of novel antipsychotics CNS Spectrums 11 2001 912 918
5. Physician’s Desk Reference . Montvale, NJ: Medical Economics Company, 2002
6. U.S. Food and Drug Administration (2000): Center for Drug Evaluation and Research Briefing Information for Psychopharmacologic Drugs Advisory Committee Meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1.htm. Accessed May 9, 2002